RxDoctor Payments Data

Jeffrey Green, PA

Medical · Corpus Christi, TXNPI 1417956574

Payments from drug & device makers

$665in general payments, 2019–2025

Across 30 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$268
  • Regeneron Healthcare Solutions, Inc.$139
  • Alk-abello, Inc$81
  • Incyte Corporation$40
  • Sanofi$23
  • Sun Pharmaceutical Industries Inc.$20
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$665 in reported general payments places this provider in the 50th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$48,729
Medicare patients
170
Services billed
1,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast41$198,859
Humira(Cf) PenAdalimumab30$196,834
EnbrelEtanercept13$152,106
Dupixent PenDupilumab12$42,667
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$34,273
Epinephrine89$18,857
SymbicortBudesonide/Formoterol Fumarate67$15,620
Calcipotriene21$9,355
Clobetasol Propionate167$8,425
Metronidazole85$4,325
Betamethasone Dipropionate50$3,591
Triamcinolone Acetonide194$3,465
Ketoconazole222$3,137
Minocycline Hcl105$2,921
Dapsone20$2,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$19$350,96454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,490 medical providers in Texas.

Other medical in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →